15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Krystal Biotech Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $284.00 to $403.00, a moderate spread. The average target of $355.10 sits 1% above the current $351.76. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.24 next quarter toward $9.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Krystal Biotech Inc.
As of Sep, 10 of 11 firms rate KRYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KRYS EPS & revenue forecast
EPS · NEXT QUARTER
$2.24
Range $1.69 – $3.41 · 10 analysts · +32% YoY
Next period, 10 analysts expect Krystal Biotech Inc to earn $2.24 a share (range $1.69 – $3.41), versus $1.70 a year earlier. Full-year consensus is $7.87, growing to $9.40 the year after.
REVENUE · NEXT QUARTER
$144.7M
Range $121.1M – $195.1M · 10 analysts · +35% YoY
Revenue is expected to reach $144.7M (range $121.1M – $195.1M), +35.1% year-over-year. Full-year consensus is $512.6M, rising to $654.6M next year.
Top analysts covering Krystal Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KRYS.
#1
Geulah Livshits
Chardan Capital · Rank #85
Buy
$323.00-8.2% to target
Overall win rate
46%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$474.00+34.8% to target
Overall win rate
43%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$284.00-19.3% to target
Overall win rate
44%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$386.00+9.7% to target
Overall win rate
41%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$361.00+2.6% to target
Overall win rate
34%
+ Follow
KRYS stock forecast FAQ
What is KRYS's average 12-month price target?+
The 10 analysts with a live target average $355.10 for Krystal Biotech Inc over the next 12 months, ranging from a $403.00 high to a $284.00 low.
Is KRYS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KRYS?+
The Street-high target is $403.00 (TD Cowen), and the Street-low is $284.00 (Guggenheim). The average of all 10 active targets is $355.10.
How many Wall Street analysts cover KRYS?+
11 analysts have an active rating on Krystal Biotech Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering KRYS?+
Among analysts who currently cover KRYS, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #85). Their current call is Buy with a $323.00 target.
What is Krystal Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $2.24 per share (range $1.69 – $3.41) across 10 analysts. Full-year EPS is projected at $7.87, rising to $9.40 the following year.
How much revenue is Krystal Biotech Inc expected to report next quarter?+
Consensus revenue is $144.7M (range $121.1M – $195.1M). Full-year revenue is projected at $512.6M, growing to $654.6M next year.
Have analysts been upgrading or downgrading KRYS lately?+
As of Sep, 10 of 11 firms rate KRYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KRYS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
